NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an agreement making Teva Pharmaceuticals the exclusive distributor of its SelectMDx prostate cancer test in Israel.
Under the terms of the three-year deal, Teva will send patient samples to MDxHealth's clinical diagnostic laboratory in the Netherlands for analysis. Teva will also reimburse MDxHealth for all testing services. Additional terms were not disclosed.
"The SelectMDx test opens up the opportunity to address a broader segment of patients at risk for prostate cancer and being considered for an invasive biopsy procedure," Sapir Avinoam, vice president and general manager of Teva Israel, said in a statement. "The test further complements our portfolio of molecular tests and services, allowing us to better serve our physician base and improve patient outcomes."
SelectMDx is a urine-based assay designed to identify men at high risk for aggressive prostate cancer who may benefit from early detection and an initial prostate biopsy or MRI, as well as men at very low risk for the disease.